Transforming growth factor-beta in osteolytic breast cancer bone metastases.
about
The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and TreatmentA novel 3-D mineralized tumor model to study breast cancer bone metastasisTgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growthThe reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model.Treatment of multiple myeloma bone disease: experimental and clinical data.The properties of high-dimensional data spaces: implications for exploring gene and protein expression data.Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells.Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT).TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progressionInterleukin-6 in bone metastasis and cancer progression.Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis.An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase.RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.TGF-beta regulates the mechanical properties and composition of bone matrix.Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.The molecular pathogenesis of osteosarcoma: a reviewGAS6 receptor status is associated with dormancy and bone metastatic tumor formationMathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells.Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.Pre-osteoblastic MC3T3-E1 cells promote breast cancer growth in bone in a murine xenograft model.Pro-tumorigenic effects of transforming growth factor beta 1 in canine osteosarcoma.The Inhibitory Effects of Forsythia Koreana Extracts on the Metastatic Ability of Breast Cancer Cells and Bone Resorption by Osteoclasts.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Emerging therapeutic targets in breast cancer bone metastasis.Therapeutic targeting of osteoclast function and pathways.Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.Animal model for mammary tumor growth in the bone microenvironment.Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction.Cathepsin K expression and activity in canine osteosarcoma.Nuclear targeting of a midregion PTHrP fragment is necessary for stimulating growth in breast cancer cells.Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis.The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).Bone morphogenetic proteins.Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.Upregulation of long non-coding RNA HIF 1α-anti-sense 1 induced by transforming growth factor-β-mediated targeting of sirtuin 1 promotes osteoblastic differentiation of human bone marrow stromal cells.Animal Models of Cancer-Associated Hypercalcemia.
P2860
Q26865458-BA373073-258B-4399-9061-18310E701AE7Q28472598-510F835F-4913-4A67-AE3B-8D3473CB79DCQ28473419-F5764584-A3A9-46ED-8CD5-6F6A2E046A83Q30415248-8122073F-DB98-41F3-8B4C-419D234B1B1DQ30868833-2116B49D-8340-4B24-B6D4-1E6B8DBE4ECDQ31140694-FA22F8E3-9480-4CD3-92A3-2F7A465FF2A3Q33416408-C3F64790-0E43-41BC-B580-73A26B33F605Q33862570-122F7CE9-C29B-4F94-BA83-741869BBD531Q33936542-3ED86FF6-300E-4A4E-8A38-FE6CB87CEBFFQ34051820-DE767F5C-1824-4C66-8083-1241C7838809Q34087005-BED91F8B-9F05-45F8-98C3-1CA1913A2AE3Q34125314-3E7A529F-D0FA-4390-BBA8-862B3B917485Q34181380-F482CCF4-3FF2-423B-9307-A0E6E287F5B6Q34209272-8290E8D3-F92D-42C9-B940-D46A823E5DB3Q34245000-EF0BBF39-A0BA-4784-B450-63AFC75899B4Q34485147-81C0F6ED-165A-4B3F-BE4A-171B2DD09D30Q34629074-0559C459-0626-4D1B-96AC-50D47685D883Q34700694-C834795C-F628-43C8-A568-028901CE1E54Q34806153-E1C39B66-1FAC-4D53-A7CE-1EC92CEA0EC4Q36196768-C27A5D72-1269-4AAD-92A2-E3B884322997Q36426121-DD3DA2E6-B4C2-417C-9E6B-8E5BC026FB6DQ36640234-AF190D8F-83CA-41FD-9D03-247F94DCB01FQ36866352-BAE85050-7426-48EC-B147-6BB485F81F30Q36975041-6ED0FA0C-48D4-41ED-8190-8CFAAB460E25Q37066418-8AABF4AC-914D-421C-A57A-369111E03C85Q37187646-E944A97D-ED6E-4433-A63D-FF2E28B3E5CEQ37658767-89B2E0FF-AE37-4F0B-8252-F9834A9D08D3Q37825905-7941FB62-2C9F-49F0-A126-A4EB23CA3C81Q37990849-5AD3573E-CEF4-4ACB-98F8-231CB5300606Q38075495-C3B37A29-0B2E-4101-A6ED-142F91865A4BQ38722186-973B5EBA-77F0-4EE9-871D-087209342EBCQ39196233-CD63B2FC-46C1-4026-955C-1C4A285FA88FQ39428117-A8139F33-17AF-425C-9B17-27A4469A3FFCQ40322396-39C9D3AD-6055-42AB-85E3-E75B45FFFF2AQ41548165-8A1080C1-F5B5-406F-A915-764377672E36Q41689098-B8B9B4A2-D64F-426B-B768-76A14EDB96FFQ42556457-3687DE2A-928E-4EAF-A9BC-DBB38B84D16CQ42713030-AD7682DE-5382-4304-A432-A76B131EEB69Q43196446-CB9BC2F9-ADCC-4D47-AD74-C00EFCBC25C5Q43378586-EC35862E-D2D6-430D-A9F5-292E208EC58D
P2860
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
@ast
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
@en
type
label
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
@ast
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
@en
prefLabel
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
@ast
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
@en
P1476
Transforming growth factor-beta in osteolytic breast cancer bone metastases.
@en
P2093
John M Chirgwin
P356
10.1097/01.BLO.0000093055.96273.69
P407
P433
P577
2003-10-01T00:00:00Z